On Mar 13, 2026, BIOX reported earnings of -0.08 USD per share (EPS) for Q2 26, missing the estimate of 0.07 USD, resulting in a -212.04% surprise. Revenue reached 73.70 million, compared to an expected 97.92 million, with a -24.73% difference. The market reacted with a -17.48% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.05 USD, with revenue projected to reach 55.59 million USD, implying an decrease of -37.50% EPS, and decrease of -24.57% in Revenue from the last quarter.